<code id='57E155DCAB'></code><style id='57E155DCAB'></style>
    • <acronym id='57E155DCAB'></acronym>
      <center id='57E155DCAB'><center id='57E155DCAB'><tfoot id='57E155DCAB'></tfoot></center><abbr id='57E155DCAB'><dir id='57E155DCAB'><tfoot id='57E155DCAB'></tfoot><noframes id='57E155DCAB'>

    • <optgroup id='57E155DCAB'><strike id='57E155DCAB'><sup id='57E155DCAB'></sup></strike><code id='57E155DCAB'></code></optgroup>
        1. <b id='57E155DCAB'><label id='57E155DCAB'><select id='57E155DCAB'><dt id='57E155DCAB'><span id='57E155DCAB'></span></dt></select></label></b><u id='57E155DCAB'></u>
          <i id='57E155DCAB'><strike id='57E155DCAB'><tt id='57E155DCAB'><pre id='57E155DCAB'></pre></tt></strike></i>

          Home / knowledge / knowledge

          knowledge


          knowledge

          author:explore    Page View:83
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In